Comprehensive Assessment and Management in Contemporary Practice
Magnesium disorders are frequently underrecognized. Hypomagnesemia affects 2–15% of hospitalized patients and up to 65% of ICU patients. Magnesium serves as cofactor for over 300 enzymatic reactions and plays crucial roles in cellular energy metabolism, protein synthesis, and ion channel function. Understanding its relationships with potassium and the PTH-calcium axis proves essential for managing complex electrolyte disorders.
Fourth most abundant cation in the body, second most prevalent intracellular cation (after potassium). Total body Mg: ~25 g (1,000 mmol) — 99% intracellular (60% bone, 39% soft tissues, only 1% in ECF). This distribution explains why serum levels may not reflect total body stores.
Normal serum Mg: 1.8–2.4 mg/dL (0.75–1.0 mmol/L). Kidneys filter ~2,400 mg daily with 95% reabsorbed:
The Mg-ATP complex is the physiologically active form of ATP. Magnesium modulates Na-K-ATPase, calcium channels, cardiac conduction, neuromuscular function, and vascular tone.
One of the most common causes, affecting an estimated 30% of hospitalized alcoholic patients. Multiple mechanisms:
Chronic diarrhea (secretory > osmotic), inflammatory bowel disease, short bowel syndrome, chronic pancreatitis. Post-surgical states: extensive small bowel resection, bariatric surgery (Roux-en-Y, biliopancreatic diversion).
Refeeding syndrome risk: rapid carbohydrate administration increases cellular Mg demands while depleted stores cannot meet requirements, potentially precipitating severe hypomagnesemia.
| Category | Specific Causes | Key Clinical Features |
|---|---|---|
| Nutritional/GI | Chronic alcohol use disorder | Multiple nutrient deficiencies, withdrawal risk |
| Protein-energy malnutrition | Refeeding syndrome risk, cachexia | |
| Inflammatory bowel disease | Active inflammation, diarrhea | |
| Short bowel syndrome | Post-surgical, malabsorption | |
| Chronic diarrhea | Volume losses, secretory vs osmotic | |
| Bariatric surgery | RYGB, biliopancreatic diversion | |
| Renal Losses | Loop diuretics | Dose-dependent, concurrent hypokalemia |
| Thiazide/thiazide-like diuretics | Gitelman-like syndrome | |
| Aminoglycosides | Nephrotoxicity, duration-dependent | |
| Calcineurin inhibitors | Transplant patients, vasoconstriction | |
| Proton pump inhibitors | Long-term use, intestinal transport inhibition | |
| Gitelman syndrome | Genetic, hypocalciuria | |
| Primary aldosteronism | Hypertension, hypokalemia | |
| Endocrine | Diabetes mellitus | Osmotic diuresis, poor glycemic control |
| Hyperthyroidism | Increased clearance, hypermetabolism | |
| Primary hyperparathyroidism | Hypercalciuria, bone turnover | |
| Medications | Cisplatin, cetuximab | Cumulative dose-dependent |
| Foscarnet, pentamidine | Antiviral/anti-pneumocystis, tubular toxicity |
Often asymptomatic until Mg <1.2 mg/dL (0.5 mmol/L). Early: fatigue, weakness, irritability, muscle cramps. Progressive: Chvostek and Trousseau signs, muscle fasciculations (facial muscles are early/specific). Severe: tetany, seizures, altered mental status.
Serum Mg limitations: Up to 30% of total body Mg may be lost before serum levels decrease.
Magnesium tolerance test: 0.2 mmol/kg IV MgSO4, measure 24h urine. Retention >50% indicates deficiency (gold standard but limited clinical utility).
Fractional excretion of Mg: FEMg = (UMg × SCr) / (0.7 × SMg × UCr) × 100. In hypomagnesemia: >2% = renal wasting; <2% = extrarenal losses or inadequate intake.
| Category | Tests | Interpretation |
|---|---|---|
| Initial Labs | Fasting serum Mg, BMP, albumin, ionized Ca | <1.8 mg/dL diagnostic; check concurrent electrolytes |
| Concurrent | K, PO4, 25-OH Vit D, intact PTH | 60% have concurrent hypoK; PTH suppressed in severe deficiency |
| Renal | 24h urine Mg, FEMg, spot urine Mg/Cr ratio, Cr/eGFR | FEMg >2% = renal wasting; 24h <120 mg/day appropriate in deficiency |
| Specialized | Mg tolerance test, genetic testing | Gold standard for body stores; suspected inherited disorders |
| History | Medications (diuretics, PPIs, antibiotics), alcohol, nutrition, family hx | Identify modifiable causes |
| Exam | Reflexes, Chvostek/Trousseau, CV evaluation, malabsorption signs | Neuromuscular hyperexcitability, arrhythmias |
| Formulation | Elemental Mg Content | Absorption | Notes |
|---|---|---|---|
| Mg oxide | 60% | Poor (4%) | Frequently causes diarrhea; not recommended |
| Mg citrate | 16% | Good | Widely available; osmotic laxative effect |
| Mg gluconate | 5% | Good | Well tolerated, low elemental content |
| Mg glycinate/bisglycinate | Variable | Excellent | Optimal absorption with minimal GI side effects |
Dosing: 400–800 mg elemental Mg daily, divided into 2–3 doses. Treatment duration: weeks to months depending on etiology.
1–2 g (4–8 mmol) MgSO4 in 50–100 mL NS IV over 1–2 hours, then 6 g (24 mmol) over 24 hours by continuous infusion. Monitor serum levels every 6–8 hours.
Weekly or twice-weekly infusions of 2–4 g MgSO4 for patients with ongoing losses or malabsorption.
Rarely occurs with normal renal function. CKD stages 4–5 (eGFR <30) significantly impairs Mg elimination. Common sources: excessive IV MgSO4 (eclampsia treatment), Mg-containing antacids/laxatives in renal impairment, Epsom salt ingestion.
| Category | Specific Causes | Risk Factors |
|---|---|---|
| Renal | CKD stages 4–5 | eGFR <30 mL/min/1.73m² |
| AKI | Oliguria, volume overload | |
| ESRD | Dialysis patients between sessions | |
| Exogenous | IV MgSO4 overdose | Eclampsia treatment, cardiac arrest |
| Mg-containing antacids | Chronic use in renal dysfunction | |
| Mg-containing laxatives | Cathartic abuse, renal impairment | |
| Epsom salt ingestion | Therapeutic or intentional overdose | |
| Endocrine | Primary hyperparathyroidism | Bone resorption, hypercalcemia |
| Hypothyroidism, Addison’s disease | Reduced clearance |
| Serum Mg (mg/dL) | Serum Mg (mmol/L) | Clinical Manifestations |
|---|---|---|
| 4.8–6.0 | 2.0–2.5 | Generally asymptomatic; mild sedation possible |
| 6.0–10.8 | 2.5–4.5 | Absent DTRs, weakness, confusion |
| 10.8–15.6 | 4.5–6.5 | Respiratory depression, complete heart block |
| >15.6 | >6.5 | Cardiac arrest, coma |
Preferred laxatives in CKD: PEG-based (MiraLAX), docusate sodium, senna/bisacodyl cautiously, lubiprostone, linaclotide. Avoid all Mg-containing products (milk of magnesia, Mg citrate, Epsom salts).
Incidence: 5–10% of long-term users. Mechanism: impaired intestinal Mg absorption via TRPM6/TRPM7 channel inhibition + altered gastric pH affecting Mg solubility. Dose-dependent and duration-related (typically months to years before manifestation).
Suspect in long-term PPI users with neuromuscular symptoms, especially with concurrent hypoK and hypoCa resistant to replacement. Consider H2 receptor antagonists as alternatives.
Inhibit NKCC2 in the thick ascending limb (where 60% of Mg is reabsorbed). Furosemide has greatest Mg-wasting potential. Losses increase proportionally with dose; patients on >80 mg daily furosemide equivalent are at particular risk.
Affect NCCT in the DCT. Chlorthalidone and indapamide (longer half-lives) may produce more sustained Mg losses. Chronic use produces a “Gitelman syndrome phenocopy”: hypoMg, hypoK, hypocalciuria.
Monitoring: Baseline Mg, then at 1–2 weeks, then every 3–6 months. More frequent with dose changes or addition of other Mg-depleting drugs.
Potassium-sparing diuretics (amiloride, spironolactone) may partially mitigate Mg losses but do not completely prevent depletion.
One of the most clinically significant electrolyte interactions. Approximately 60% of hypoMg patients have concurrent hypoK.